Pediatr Pulmonol. 2021 Oct;56(10):3209-3216. doi: 10.1002/ppul.25569. Epub 2021 Jul 28.

Comparison of the predictive value of area under the curve versus maximum serum concentration of intravenous tobramycin in cystic fibrosis patients treated for an acute pulmonary exacerbation.

Pediatric pulmonology

Katherine B Landmesser, Elizabeth B Autry, Brian M Gardner, Katherine A Bosko, Aric Schadler, Robert J Kuhn

PMID: 34241975 DOI: 10.1002/ppul.25569

Abstract

OBJECTIVES: The primary objective of this study was to compare the therapeutic predictive value of area under the curve (AUC

METHODS: A retrospective review was conducted in patients aged at least 1 month with a diagnosis of CF receiving IV tobramycin for treatment of a PsA APE and admitted to the University of Kentucky between August 2015 and August 2019. Patients were excluded if they had no growth of PsA on sputum culture or if two postdose tobramycin levels were not obtained following a dose adjustment of ≥20%.

RESULTS: A total of 44 pediatric and 107 adult patient encounters met inclusion criteria. In patients with therapeutic success (n = 91), 75.8% had an AUC

CONCLUSIONS: The results of this study indicate that both AUC

© 2021 Wiley Periodicals LLC.

Keywords: antibiotic therapy; cystic fibrosis; pharmacodynamics; pharmacokinetics; tobramycin

References

1. Bhagirath A, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC pulmonary medicine. 2016;16(1):174. - PubMed
2. Kerem E, Viviani L, Zolin A, et al, ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J. 2014;43(1):125-133. - PubMed
3. Flume PA, Mogayzel PJ, Robinson KA, et al, Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009;180(9):802-808. - PubMed
4. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 1995;28(2):143-160. - PubMed
5. Kelvin H, Tan V, Mulheran M, Knox AJ, Smyth AR. Aminoglycoside prescribing and surveillance in cystic fibrosis. Am J Respir Crit Care Med. 2003;167:819-823. - PubMed
6. Coulthard KP, Peckham DG, Conway SP, Smith CA, Bell J, Turnidge J. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis-caution with trough concentrations. J Cyst Fibros. 2007;6(2):125-130. - PubMed
7. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999;36(2):89-98. - PubMed
8. Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest. 1997;112(5):1208-1213. - PubMed
9. ZEMDRI® (plazomicin) injection package insert. Achaogen Inc. Revised 1/2020. - PubMed
10. University of Kentucky Department of Pharmacy. 2020. University of Kentucky Blue Book: Therapeutic Drug Monitoring. : Retrieved from http://careweb/ICISdocs/Aminoglycoside%20Blue%20Book_061720.pdf - PubMed
11. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549-1555. - PubMed
12. Prescott WA, Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy. 2010;30(1):95-108. - PubMed
13. Khwaja A. Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for acute kidney injury. Nephron Clin Pract. 2012;120:179-184. - PubMed
14. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, Relling MV editors., Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics, Inc; 1992:14-1-1442. - PubMed
15. VandenBussche HL, Homnick DN. Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis. J Pediatr Pharmacol Ther. 2012;17(1):67-77. - PubMed
16. Young DC, Zobell JT, Stockmann C, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatr Pulmonol. 2013;48(11):1047-1061. - PubMed
17. Zobell JT, Epps K, Kittell F, et al. Tobramycin and Beta-Lactam antibiotic use in cystic fibrosis exacerbations: a pharmacist approach. J Pediatr Pharmacol Ther. 2016;21(3):239-246. - PubMed
18. Smyth AR, Bhatt J, Nevitt SJ. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2017;3(3):002009. - PubMed
19. Master V, Roberts GW, Coulthard KP, et al. Efficacy of once-daily tobramycin monotherapy in acute pulmonary exacerbation of cystic fibrosis. Pediatr Pulmonol. 2001;31(5):367-376. - PubMed
20. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J. 2002;19:303-309. - PubMed
21. Smyth A, Tan KH, Hyman-Taylor P, et al, TOPIC Study Group. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Lancet. 2005;365(9459):573-578. - PubMed

Publication Types

• Journal Article